Zymeworks Inc. (NASDAQ:ZYME) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET

Company Participants

Shrinal Inamdar - Director, Investor Relations
Leone Patterson - Executive Vice President, Chief Business and Financial Officer
Paul Moore - Chief Scientific Officer
Kenneth Galbraith - Chair and Chief executive Officer

Conference Call Participants

Stephen Willey - Stifel
Ashiq Mubarack - Citi
Brian Cheng - JPMorgan
Jon Miller - Evercore ISI
Derek Achila - Wells Fargo

Operator

Hello. Thank you for standing by. This is the conference operator. Welcome to Zymeworks First Quarter 2024 Results Conference Call and Webcast. As a reminder, all participants are in a listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. [Operator Instructions]

I would now like to turn the conference over to Shrinal Inamdar, Director of Investor Relations. You may begin.

Shrinal Inamdar

Thank you, operator. Good afternoon, everyone and thank you for joining our third quarter 2024 results conference call.

Before we begin, I would like to remind you that we'll be making a number of forward-looking statements during this call, including without limitation, those forward-looking statements identified in our slides and the accompanying oral commentary.

Forward-looking statements are based on our current expectations and various assumptions, and are subject to the usual risks and uncertainties associated with companies in our industry and at our stage of development. For a discussion of these risks and uncertainties, we refer you to our latest SEC filings as found on our website and as part of the SEC.

In a moment, I will hand over to Leone Patterson, our Executive Vice President and Chief Business and Financial Officer. Leone joined our leadership team in September 2024 and today Leone will be discussing recent corporate updates along with financial results for our third quarter 2024. Following this, Dr. Paul Moore, our Chief Scientific Officer, will talk about key highlights for our third quarter, including the initiation of a first patient dose in the Phase 1 trial of our first bispecific 2 plus 1 [ph] mesothelin T cell engager ZW171. At the end of the call, Leone, Paul and Ken Galbraith, our Chair and CEO, will be available for Q&A.

As a reminder, the audio and slides from this call will also be available on the Zymeworks website later today.

I will now turn the call over to Leone.

Leone Patterson

Thank you for the introduction, Shrinal, and thank you all for joining us today.